Finance

Beta
Senarai
Sektor ekuiti
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Buka
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.21%
1,091.51
-2.30
-0.21%
—1,093.811,096.521,100.221,091.51——
SIXC
Communications
SIXC
Communications
SIXC
+0.22%
610.11
+1.34
+0.22%
—608.77608.77612.97608.77——
SIXE
Energy
SIXE
Energy
SIXE
-1.34%
1,237.98
-16.83
-1.34%
—1,254.811,253.011,253.871,226.33——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.93%
1,744.71
-16.40
-0.93%
—1,761.111,764.271,766.881,744.71——
SIXM
Financials
SIXM
Financials
SIXM
-0.37%
640.18
-2.40
-0.37%
—642.58644.87648.48640.18——
SIXR
Staples
SIXR
Staples
SIXR
-0.18%
849.58
-1.55
-0.18%
—851.13855.66858.75845.56——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0.23%
217.48
-0.50
-0.23%
—217.98217.98218.65216.88——
SIXT
Technology
SIXT
Technology
SIXT
+1.52%
3,260.69
+48.86
+1.52%
—3,211.833,227.213,268.383,226.55——
SIXU
Utilities
SIXU
Utilities
SIXU
-0.69%
942.45
-6.53
-0.69%
—948.98948.58957.83941.97——
SIXV
Health care
SIXV
Health care
SIXV
-0.52%
1,466.80
-7.72
-0.52%
—1,474.521,479.031,481.041,466.80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.22%
2,397.50
+5.38
+0.22%
—2,392.122,396.952,421.222,382.32——
VXRT:OTCMKTS
Vaxart Inc
USD 0.77
0.00%
(0.00) 1H
1 Mei, 4:00:00 PTG GMT-4  ·   USD
Semua simbol
SimbolPriceChange% Change
Generating top insights for VXRT...
Buka
USD 0.77
High
USD 0.79
Low
USD 0.75
Mkt. cap
185.29J
Avg. vol.
458.71K
Volume
781.95K
P/E ratio
10.86
52-wk high
USD 0.84
52-wk low
USD 0.26
EPS
USD 0.07
Beta
1.31
Shares outstanding
241.41J
No. of employees
65
News stories
From sources across the web
Stock Titan
Stock Titan
·
2 hari lalu
[EFFECT] Vaxart, Inc. SEC Filing
Profil
Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus. It was founded in 2004 by Sean Tucker. Originally incorporated as West Coast Biologicals, Inc. in California in 2004, the company later changed its name to Vaxart, Inc. in July 2007, after reincorporating in Delaware. A significant development in the company's history was the reverse merger with Aviragen Therapeutics, Inc. on February 13, 2018, which led to Vaxart becoming a wholly owned subsidiary of Aviragen. Post-merger, the company continued as Vaxart, Inc. Vaxart's development portfolio includes a range of oral vaccines targeting infectious diseases such as norovirus, COVID-19, and seasonal influenza, as well as therapeutic vaccines like those targeting HPV. Wikipedia
About Vaxart Inc
CEO-
Employees65
FoundedMac 2004
HeadquartersSouth San Francisco, California, Amerika Syarikat
Sector-
Websitevaxart.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mac 2025
Jun 2025
Sep 2025
Dis 2025
Revenue
20.88J
39.73J
72.41J
104.24J
Cost of goods sold
30.74J
49.74J
75.95J
45.15J
Cost of revenue
30.74J
49.74J
75.95J
45.15J
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.07J
4.60J
4.28J
3.67J
Operating expense
5.07J
4.60J
4.28J
3.67J
Total operating expenses
35.81J
54.33J
80.22J
48.82J
Operating income
-14.94J
-14.60J
-7.81J
55.42J
Other non operating income
-1.00K
-1.00K
-7.00K
-35.00K
EBT including unusual items
-15.50J
-14.97J
-8.12J
55.39J
EBT excluding unusual items
-15.50J
-14.97J
-8.12J
55.39J
Income tax expense
95.00K
20.00K
17.00K
344.00K
Effective tax rate
-0.61%
-0.13%
-0.21%
0.62%
Other operating expenses
-
-
-
-
Net income
-15.59J
-14.99J
-8.14J
55.04J
Net profit margin
-74.68%
-37.72%
-11.24%
52.81%
Earnings per share
-0.07
-0.07
-0.04
0.24
Interest and investment income
437.00K
310.00K
302.00K
547.00K
Interest expense
-997.00K
-672.00K
-608.00K
-546.00K
Net interest expenses
-560.00K
-362.00K
-306.00K
1.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-12.69J
-12.41J
-5.73J
57.48J
Gain or loss from assets sale
-
-
5.00K
33.00K
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

Tugasan saya
Anda belum membuat tugasan lagi
Tugasan anda akan dipaparkan di sini. Jadualkan tugasan dan manfaatkan Google Finance semasa anda tiada.
Templat
Ringkasan senarai amatan
Analisis prapasaran harian bagi senarai amatan anda
Pendapatan Akan Datang
Laporan pendapatan akan datang dalam minggu ini
Kemudahubahan & Jumlah yang Tidak Normal
Amaran awal kemudahubahan dan jumlah hari ini
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer